Humoral Immunity Study After a Booster Dose of Soberana Plus (FINLAY-FR-1A) Vaccine Against COVID-19
Humoral Immunity
About this trial
This is an interventional prevention trial for Humoral Immunity focused on measuring COVID-19, SARS-CoV-2, Humoral immunity, Booster dose
Eligibility Criteria
Inclusion Criteria: Age 18-80 y.o.; More that 4 months after the previous vaccination against COVID-19; No COVID-19 infection registered within 30 days prior to Soberana Plus administration. Exclusion Criteria: Age less than 18 y.o. or more than 80 y.o.; Less than 4 months after the previous vaccination against COVID-19; COVID-19 infection registered within 30 days prior to Soberana Plus administration.
Sites / Locations
- Gomel State Medical University
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Booster dose administration to younger participants
Booster dose administration to older participants
Participants 18-25 y.o. take a booster dose of vaccine against COVID-19 (Soberana Plus (FINLAY-FR-1A), Republic of Cuba)
Participants 26-80 y.o. take a booster dose of vaccine against COVID-19 (Soberana Plus (FINLAY-FR-1A) Republic of Cuba)